Study findings from E.A. Macgregor et al provide new insights into adverse drug reactions

According to a study from London, the United Kingdom, "Objective.- To assess the safety and tolerability profile of the 5-HT1B/1D agonist frovatriptan (Frova ®, Endo Pharmaceuticals Inc., Chadds Ford, PA, USA) when used as a 6-day regimen for the short-term prevention of menstrual migraine scheduled over multiple perimenstrual periods. Background.- Two randomized controlled trials have established the efficacy of a 6-day regimen of frovatriptan for reducing the incidence and severity of menstrual migraine over 1 to 3 perimenstrual periods; long-term data are needed to further assess the safety and tolerability profile of this regimen."

"Methods.- Two multinational...

Want to see the full article?

• Purchase this article for only $3.00